The present disclosure includes genetically engineered, non-pathogenic Streptomyces bacterium with exogenous, non-native Thaxtomin A (ThxA) biosynthetic gene clusters conferring the genetically engineered, non-pathogenic Streptomyces bacterium with the ability to produce thaxtomin A. Also included are methods of providing thaxtominproducing capability in non-native Streptomyces bacterial strains, methods of producing thaxtomin compounds with the genetically engineered Streptomyces bacteria of the present disclosure, and methods of producing thaxtomin compounds and nitro-tryptophan analogs, and fluorinated thaxtomin compounds, analogs, and intermediates with the genetically engineered Streptomyces bacteria of the present disclosure.
本公开涉及具有外源非自然Thaxtomin A(ThxA)
生物合成
基因簇的
基因工程非致病链霉菌,使得这些
基因工程非致病链霉菌具有生产thaxtomin A的能力。还包括在非自然链霉菌菌株中提供生产thaxtomin的能力的方法,使用本公开的
基因工程链霉菌生产thaxtomin化合物的方法,以及使用本公开的
基因工程链霉菌生产thaxtomin化合物、硝基色
氨酸类似物和
氟代thaxtomin化合物、类似物和中间体的方法。